Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Products

Set Alert for Products

Generics Explore this Topic

Set Alert for Generics

German Funds Deny Tenders Link To Shortages

Leaked political proposals to stop German insurance funds awarding tender contracts to just one supplier would not help to prevent drug shortages, insists the leading AOK group of funds.

Germany Generic Drugs

Actavis Faces Wait Until 2027 On US Pennsaid

Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing evidence” and “unpersuasive arguments” over obviousness.

Intellectual Property Generic Drugs

Mylan Fails To Unblock Path On German Glatiramer

A German higher regional court has upheld an injunction barring Mylan from marketing its Clift rival to Teva’s Copaxone 40mg/ml multiple sclerosis treatment.

Intellectual Property Germany
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Canadian Originators Are Free To Try Again

Having unsuccessfully asserted a patent under the previous legal framework in Canada does not preclude an originator from trying again following legislative amendments enacted in 2017, the country’s Federal Court of Appeal has ruled in a decision on Pfizer’s Nivestym filgrastim biosimilar.

Canada Intellectual Property

Dutch Watchdog Questions Conditional Rebates For Biologics

Originators that make discounts on biologic list prices conditional on hospitals not switching treatment to anti-TNF biosimilars may be breaching competition law, the Netherlands’ competition authority is warning.

Biosimilars Netherlands

Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Biosimilars Strategy
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Alvogen Strikes Deals For Pfenex’ Teriparatide

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

Deals Value-Added Medicines

Value Added Medicines Hold Promise Despite Challenges

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Value-Added Medicines Market Intelligence

Early Dialogue And Patient Involvement Can Unlock Value

Recognizing the benefits of value added medicines in European hospital settings can help patients and healthcare professionals, a KPMG report commissioned by Medicines for Europe suggests.

Value-Added Medicines Europe
See All
UsernamePublicRestriction

Register

Advertisement